Literature DB >> 29203639

A Knock-In Tristetraprolin (TTP) Zinc Finger Point Mutation in Mice: Comparison with Complete TTP Deficiency.

Wi S Lai1, Deborah J Stumpo1, Lianqun Qiu1, Roberta Faccio2, Perry J Blackshear3,4.   

Abstract

Tristetraprolin (TTP) is a tandem CCCH zinc finger protein that can bind to AU-rich element-containing mRNAs and promote their decay. TTP knockout mice develop a severe inflammatory syndrome, largely due to excess tumor necrosis factor (TNF), whose mRNA is a direct target of TTP binding and destabilization. TTP's RNA binding activity and its ability to promote mRNA decay are lost when one of the zinc-coordinating residues of either zinc finger is mutated. To address several long-standing questions about TTP activity in intact animals, we developed a knock-in mouse with a cysteine-to-arginine mutation within the first zinc finger. Homozygous knock-in mice developed a severe inflammatory syndrome that was essentially identical to that of complete TTP deficiency, suggesting that TTP's critical anti-inflammatory role in mammalian physiology is secondary to its ability to bind RNA. In addition, there was no evidence for a "dominant-negative" effect of the mutant allele in heterozygotes, as suggested by previous experiments. Finally, mRNA decay experiments in mutant macrophages demonstrated that TTP can regulate the stability of its own mRNA, albeit to a minor extent. These studies suggest that RNA binding is an essential first step in the physiological activities of members of this protein family.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  AU-rich elements; RNA binding proteins; inflammation; mRNA decay; zinc finger proteins

Mesh:

Substances:

Year:  2018        PMID: 29203639      PMCID: PMC5789023          DOI: 10.1128/MCB.00488-17

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction.

Authors:  E Carballo; G S Gilkeson; P J Blackshear
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Posttranscriptional regulation of cytokine expression.

Authors:  Pavel Kovarik; Florian Ebner; Vitaly Sedlyarov
Journal:  Cytokine       Date:  2015-11-14       Impact factor: 3.861

3.  Interactions of CCCH zinc finger proteins with mRNA: non-binding tristetraprolin mutants exert an inhibitory effect on degradation of AU-rich element-containing mRNAs.

Authors:  Wi S Lai; Elizabeth A Kennington; Perry J Blackshear
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

Review 4.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

5.  Tristetraprolin (TTP) coordinately regulates primary and secondary cellular responses to proinflammatory stimuli.

Authors:  Lian-Qun Qiu; Wi S Lai; Alyce Bradbury; Darryl C Zeldin; Perry J Blackshear
Journal:  J Leukoc Biol       Date:  2015-02-05       Impact factor: 4.962

6.  Tristetraprolin and its family members can promote the cell-free deadenylation of AU-rich element-containing mRNAs by poly(A) ribonuclease.

Authors:  Wi S Lai; Elizabeth A Kennington; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 7.  Phosphorylation site analysis of the anti-inflammatory and mRNA-destabilizing protein tristetraprolin.

Authors:  Heping Cao; Leesa J Deterding; Perry J Blackshear
Journal:  Expert Rev Proteomics       Date:  2007-12       Impact factor: 3.940

8.  RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling.

Authors:  Jian Liang; Tianhua Lei; Yuting Song; Natalie Yanes; Yongfen Qi; Mingui Fu
Journal:  J Biol Chem       Date:  2009-09-08       Impact factor: 5.157

9.  Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies.

Authors:  Sonika Patial; Alan D Curtis; Wi S Lai; Deborah J Stumpo; Georgette D Hill; Gordon P Flake; Mark D Mannie; Perry J Blackshear
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  5 in total

1.  Importance of the Conserved Carboxyl-Terminal CNOT1 Binding Domain to Tristetraprolin Activity In Vivo.

Authors:  Wi S Lai; Deborah J Stumpo; Melissa L Wells; Artiom Gruzdev; Stephanie N Hicks; Cindo O Nicholson; Zhengfeng Yang; Roberta Faccio; Michael W Webster; Lori A Passmore; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2019-06-13       Impact factor: 4.272

Review 2.  The tandem zinc finger RNA binding domain of members of the tristetraprolin protein family.

Authors:  Wi S Lai; Melissa L Wells; Lalith Perera; Perry J Blackshear
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-03-12       Impact factor: 9.957

3.  A post-transcriptional regulon controlled by TtpA, the single tristetraprolin family member expressed in Dictyostelium discoideum.

Authors:  Wenli Bai; Melissa L Wells; Wi S Lai; Stephanie N Hicks; Adam B Burkholder; Lalith Perera; Alan R Kimmel; Perry J Blackshear
Journal:  Nucleic Acids Res       Date:  2021-11-18       Impact factor: 16.971

4.  Tristetraprolin targets Nos2 expression in the colonic epithelium.

Authors:  Melanie A Eshelman; Stephen M Matthews; Emily M Schleicher; Rebecca M Fleeman; Yuka Imamura Kawasawa; Deborah J Stumpo; Perry J Blackshear; Walter A Koltun; Faoud T Ishmael; Gregory S Yochum
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

Review 5.  Conceptual Advances in Control of Inflammation by the RNA-Binding Protein Tristetraprolin.

Authors:  Pavel Kovarik; Annika Bestehorn; Jeanne Fesselet
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.